Antivirals for COVID-19: A critical review | Zendy

Andri Frediansyah | Zendy; Ruchi Tiwari | Zendy; Khan Sharun | Zendy; Kuldeep Dhama | Zendy; Harapan Harapan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antivirals for COVID-19: A critical review

Author(s) -

Andri Frediansyah,

Ruchi Tiwari,

Khan Sharun,

Kuldeep Dhama,

Harapan Harapan

Publication year - 2020

Publication title -

clinical epidemiology and global health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.361

H-Index - 13

eISSN - 2452-0918

pISSN - 2213-3984

DOI - 10.1016/j.cegh.2020.07.006

Subject(s) - pandemic , covid-19 , medicine , coronavirus , clinical trial , pharmacology , drug , virology , drug development , neuraminidase , docking (animal) , drug discovery , disease , infectious disease (medical specialty) , bioinformatics , biology , virus , nursing , outbreak

No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess the efficacy of these antivirals are ongoing, this review highlights important information including docking and modeling analyses, in vitro studies, as well as results from clinical uses of these antivirals against COVID-19 pandemic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research